Beyond BRCA1/2, HRD score calculated by the sum of LOH, TAI, LST scores was also identified as a biomarker since patients with high HRD scores were reported to respond well to PARPi treatment in breast and ovarian cancer [12, 13]. This evidence concerns the gene BRCA1 and ovarian cancer.